Abstract:Ethnopharmacological relevance: Extracts from Ginkgo biloba L. leaves confer their therapeutic effects through the synergistic actions of flavonoid and terpenoid components, but some non-flavonoid and non-terpenoid components also exist in this extract. In the study of this paper, an investigation was carried out to compare the pharmacokinetic parameters of fourteen compounds to clarify the influences of non-flavonoid and non-terpenoid fraction (WEF) on the pharmacokinetics profile of the flavonoid fraction (FF) and the terpene lactone fraction (TLF) from Ginkgo biloba extracts. Materials and methods: A selective and sensitive UPLC-MS/MS method was established to determine the plasma concentrations of the fourteen compounds to compare the pharmacokinetic parameters after orally administration of FF, TLF, FF-WEF, FF-TLF, TLF-WEF and FF-TLF-WEF with approximately the same dose. At different time points, the concentration of rutin (1), isoquercitrin (2), quercetin 3-O-[4-O-(-β-D-glucosyl)-α-L-rhamnoside] (3), ginkgolide C (4), bilobalide (5), quercitrin (6), ginkgolide B (7), ginkgolide A (8), luteolin (9), quercetin (10), apigenin (11), kaempferol (12), isorhamnetin (13), genkwanin (14) in rat plasma were determined and main pharmacokinetic parameters including T1/2, Tmax, Cmax and AUC were calculated using the DAS 3.2 software package. The statistical analysis was performed using the Student׳s t-test with P<0.05 as the level of significance. Results: FF and WEF had no effect on the pharmacokinetic behaviors and parameters of the four terpene lactones, but the pharmacokinetic profiles and parameters of flavonoids changed while co-administered with non-flavonoid components. It was found that Cmax and AUC of six flavonoid aglycones in group FF-WEF, FF-TLF and FF-TLF-WEF had varying degrees of reduction in comparison with group FF, especially in group FF-TLF-WEF. On the contrary, the values of Cmax, Tmax and AUC of four flavonoid glycosides in group FF-TLF-WEF were significantly increased compared with those in group FF. Conclusions: These results indicate that non-flavonoid components in Ginkgo biloba extracts could increase the absorption and improve the bioavailability of flavonoid glycosides but decrease the absorption and reduce the bioavailability of flavonoid aglycones.

The Potential Drug-Drug Interactions of Ginkgolide B Mediated by Renal Transporters

Influence of Organic Anion Transporter 1/3 on the Pharmacokinetics and Renal Excretion of Ginkgolides and Bilobalide.

Effects of Ginkgo Biloba Extract on Pharmacokinetics and Pharmacodynamics of Tolbutamide and Midazolam in Healthy Volunteers

[Effect of Cyclosporine A on the Pharmacokinetics of Ginkgolide B in Rats].

Molecular Mechanisms Governing Different Pharmacokinetics of Ginsenosides and Potential for Ginsenoside-Perpetrated Herb-Drug Interactions on Oatp1b3

Synthesis, in Silico and in Vivo Blood Brain Barrier Permeability of Ginkgolide B Cinnamate.

Eexrerimental Study on the Effect of Ginkgo Biloba Extract on Cytochrome P450 Isozymes CYP1A2

The characterisation of the in vitro metabolism and transport of 6-hydroxykynurenic acid, an important constituent of Ginkgo biloba extracts

Effects of Ginkgolide B on the Pharmacokinetics and Pharmacodynamics of Diclofenac, a Substrate of Cytochrome P450 2C9, in Rats

A Pharmacokinetic and Pharmacodynamic Study of Drug-Drug Interaction Between Ginsenoside Rg1, Ginsenoside Rb1 and Schizandrin after Intravenous Administration to Rats

Interactions of pharmacokinetic profile of different parts from Ginkgo biloba extract in rats

Bilobetin Induces Kidney Injury by Influencing Cgmp-Mediated AQP-2 Trafficking and Podocyte Cell Cycle Arrest.

Discovery and Characterization of the Key Constituents in Ginkgo biloba Leaf Extract With Potent Inhibitory Effects on Human UDP-Glucuronosyltransferase 1A1

Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry

Transport of ginkgolides with different lipophilicities based on an hCMEC/D3 cell monolayer as a blood-brain barrier cell model

Polymeric Nanoparticles-Based Brain Delivery with Improved Therapeutic Efficacy of Ginkgolide B in Parkinson’s Disease

Pharmacokintics of the Ginkgo Bfollowing Intravenous Administration of Ginkgo B Emulsion in Rats

Human Pharmacokinetics of Ginkgo Terpene Lactones and Impact of Carboxylation in Blood on Their Platelet-Activating Factor Antagonistic Activity

Enhancing both oral bioavailability and anti-ischemic stroke efficacy of ginkgolide B by preparing nanocrystals self-stabilized Pickering nano-emulsion

Simultaneous Determination of Eight Bioactive Compounds by LC-MS/MS and Its Application to the Pharmacokinetics, Liver First-Pass Effect, Liver and Brain Distribution of Orally Administrated Gouteng-Baitouweng (GB) in Rats.

Potential Involvement of Organic Anion Transporters in Drug Interactions with Shuganning Injection, a Traditional Chinese Patent Medicine